Gossamer Bio Receives Optimistic Buy Rating Amid Strong Phase 3 Study Progress and Competitive Landscape

Analyst Joseph Schwartz maintains a Buy rating and $6.00 price target for Gossamer Bio, citing strong progress in their Phase 3 PROSERA study for seralutinib in treating pulmonary arterial hypertension. The study exceeded expectations, and the updated baseline characteristics suggest a positive response to the treatment. Despite competition from Merck's sotatercept, Schwartz believes there is still an opportunity for seralutinib to establish its place in the treatment landscape.

Gossamer Bio, Inc. (Nasdaq: GOSS) has announced the completion of enrollment in its ongoing Phase 3 PROSERA study, which evaluates seralutinib for the treatment of pulmonary arterial hypertension (PAH). The study, which is a double-blind, placebo-controlled, global registrational clinical trial, enrolled 390 patients with Functional Class II and III PAH.

The primary endpoint of the PROSERA study is the change in six-minute walk distance (6MWD) from baseline compared to placebo at week 24. Key secondary endpoints include time to clinical worsening up to week 48, and safety and tolerability. The study utilizes enrichment criteria to identify patients more likely to show a greater magnitude of effect on 6MWD at week 24, informed by the Phase 2 TORREY study.

Gossamer Bio expects to announce topline results from the PROSERA study in February 2026. Preliminary baseline characteristics align closely with the intended study population, suggesting a positive response to the treatment. The study population includes 74% of patients in Functional Class III, with a geographic distribution of 19% from North America and 81% from the rest of the world.

Analyst Joseph Schwartz maintains a Buy rating and $6.00 price target for Gossamer Bio, citing strong progress in the Phase 3 PROSERA study. Despite competition from Merck's sotatercept, Schwartz believes there is an opportunity for seralutinib to establish its place in the treatment landscape.

Gossamer Bio, a late-stage clinical biopharmaceutical company, is focused on the development and commercialization of seralutinib for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's goal is to enhance the lives of patients living with pulmonary hypertension.

References:
[1] https://www.biospace.com/press-releases/gossamer-bio-announces-completion-of-enrollment-in-registrational-phase-3-prosera-study-for-the-treatment-of-pah
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_TUA4THQV7:0-gossamer-bio-announces-completion-of-enrollment-in-registrational-phase-3-prosera-study-for-the-treatment-of-pah/